Corporate Action Notice

November 29, 2016

Ratio Change

Therapix Biosciences Ltd.
DR CUSIP: 88339A104 / DR ISIN: US88339A1043
DR Ticker Symbol: THXBY
Ratio: (DS: Underlying Shares): 1:20

BNY Mellon, at the direction of Therapix Biosciences Ltd. ("Therapix") is announcing a ratio change on the Depositary Receipt ("DR") Program from one (1) Depositary Share ("DS") representing twenty (20) Ordinary shares to one (1) DS representing forty (40) Ordinary shares.

The ratio change will result in a reverse stock split on the Therapix DSs on a basis of 1 new DS for every 2 old DSs held. The ordinary shares of Therapix will not be affected by this change.

Effective December 9, 2016, holders of Therapix will be required on a mandatory basis to surrender their DRs to BNY Mellon for cancellation and exchange on a basis of one (1) 'NEW' DS (CUSIP# 88339A203) for every two (2) 'OLD' DSs (CUSIP# 88339A104). Only whole DSs will be distributed BNY Mellon will attempt to sell any fractional DSs and distribute the cash proceeds.

BNY MELLON HAS ESTABLISHED THE FOLLOWING DATE AND RATES FOR THIS CORPORATE ACTION:

Effective Date: December 9, 2016
Exchange Rate: 1 New DS for 2 Old DSs

Old CUSIP:	88339A104
Old Ratio:	1 DS: 20 Ordinary Shares
New CUSIP:	88339A203
New Ratio:	1 DS: 40 Ordinary Shares

To learn more about Depositary Receipts and issuer programs, please contact our marketing desks:

NEW YORK
Ravi Davis
Richard J Maehr
+ 1 212 815 2267
adrdesk@bnymellon.com

LONDON
Jacek Jankowski
Vice President
+ 44 207 163 7427
jacek.jankowski@bnymellon.com

BNY MELLON